Who is sponsoring NCT00154219?

NCT00154219 is sponsored by Novartis.

What condition does NCT00154219 study?

NCT00154219 studies Osteoarthritis, Hip.

What drugs are being tested in NCT00154219?

Interventions: Lumiracoxib (drug).

What is the status of NCT00154219?

NCT00154219 is currently COMPLETED.

Last reviewed 2012-05-18 · How we verify

A 13-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Group Trial of Lumiracoxib (COX189) 100 mg o.d. in Patients With Primary Hip Osteoarthritis Using Celecoxib (200 mg o.d.) as a Positive Control

NCT00154219 Phase 3 COMPLETED

The purpose of this study is to evaluate the efficacy, tolerability, and safety of the investigational drug, lumiracoxib as compared to celecoxib and placebo in subjects with hip osteoarthritis. Both lumiracoxib and celecoxib belong to the same class of drug (COX-2 selective nonsteroidal anti-inflammatory drugs \[NSAIDs\]).

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Enrolment	1200
Start date	2004-11

Conditions

Osteoarthritis, Hip

Interventions

Lumiracoxib (drug)

Primary outcomes

WOMAC 3.1 LK questionnaire after 13 weeks of treatment
Patient's global assessment of disease activity (VAS) after 13 weeks of treatment

Countries

United States, Canada, Germany, Italy, United Kingdom